Louvain-La-Neuve, Belgium, April 24, 2017 - IBA, the world's leading provider of proton therapy solutions for the treatment of cancer, announces the delivery and rigging of three Proteus®ONE* treatment rooms in less than a week, in early April.

These centers are: The Rutherford Cancer Centre, South Wales, located in Newport (Wales, United Kingdom); Cyclhad (Cyclotron for Hadron Therapy) located in Caen (France), and Hokkaido Ohno Memorial Hospital located in Sapporo (Japan).

All three centers will be equipped with IBA's compact Proteus®ONE solution, comprising the latest technology of Image Guided, Intensity Modulated Proton Therapy. Being able to ship and rig three compact proton therapy solutions in less than a week is a world first, and only IBA, the leader in the proton therapy compact system has been able to achieve this to-date.
Jean-Louis Guelton, the Executive Vice President, IBA Manufacturing and Supply Chain, commented on this achievement: "By rigging these three gantries in less than a week, we have demonstrated the effectiveness of our supply chain growth plan. We are pursuing our team introductions and training to reach the goal of producing up to thirty Proteus®ONE solutions per year. Moreover, the construction of our new assembly line is on track to support that growth. You can count on IBA to beat this record again soon."

Siegfried Gschliesser, the President, IBA APAC, added: "We are very excited to start the rigging of our compact Proteus®ONE solution at Hokkaido Ohno Memorial Hospital. Proteus®ONE is the only compact Image Guided IMPT solution with the approval to be sold in Japan. Moreover, it is ideally fit for densely populated countries with specific land constraints such as Japan is. We are looking forward to seeing patients from Hokkaido across Japan being treated on this state of the art system."


About Proteus®ONE
Proteus®ONE is the compact intensity modulated proton therapy (IMPT) solution from IBA. It benefits from the latest technologies developed with renowned clinical institutions. Proteus®ONE is smaller, more affordable, easier to install and to operate. It is ultimately easier to finance, making this advanced radiation therapy modality available to more institutions and patients worldwide. Proteus®ONE makes proton therapy easy.


About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

*Proteus®ONE is the brand name of a configuration of the Proteus®235 in the US and Europe and a certified product in Japan.

Rad Oncology Homepage